ES2158847T3 - Mutaciones heredadas y somaticas del gen apc en el cancer colorectal del hombre. - Google Patents

Mutaciones heredadas y somaticas del gen apc en el cancer colorectal del hombre.

Info

Publication number
ES2158847T3
ES2158847T3 ES92906080T ES92906080T ES2158847T3 ES 2158847 T3 ES2158847 T3 ES 2158847T3 ES 92906080 T ES92906080 T ES 92906080T ES 92906080 T ES92906080 T ES 92906080T ES 2158847 T3 ES2158847 T3 ES 2158847T3
Authority
ES
Spain
Prior art keywords
apc
colorectal cancer
gen
injured
man
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906080T
Other languages
English (en)
Inventor
Kenneth W Kinzler
Bert Vogelstein
Rakesh Anand
Philip John Hedge
Alexander Fred Markham
Hans Albertsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Japanese Foundation for Cancer Research
Johns Hopkins University
University of Utah
Original Assignee
Syngenta Ltd
Japanese Foundation for Cancer Research
Johns Hopkins University
University of Utah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919100963A external-priority patent/GB9100963D0/en
Priority claimed from US07/741,940 external-priority patent/US5352775A/en
Application filed by Syngenta Ltd, Japanese Foundation for Cancer Research, Johns Hopkins University, University of Utah filed Critical Syngenta Ltd
Application granted granted Critical
Publication of ES2158847T3 publication Critical patent/ES2158847T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRESENTA UN GEN HUMANO DENOMINADO APC. SE PRESENTAN LOS METODOS Y KITS PARA VALORAR LAS MUTACIONES DEL GEN APC EN LOS TEJIDOS HUMANOS Y EN MUESTRAS CORPORALES. LAS MUTACIONES DEL APC TIENEN LUGAR EN PACIENTES CON POLIPOSIS ADENOMATOSA HEREDITARIA ASI COMO EN PACIENTES CON CANCER COLORECTAL ESPORADICO. EL APC SE EXPRESA EN LA MAYORIA DE LOS TEJIDOS NORMALES. ESTOS RESULTADOS HACEN PENSAR QUE EL APC ES UN SUPRESOR DE TUMORES.
ES92906080T 1991-01-16 1992-01-16 Mutaciones heredadas y somaticas del gen apc en el cancer colorectal del hombre. Expired - Lifetime ES2158847T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919100963A GB9100963D0 (en) 1991-01-16 1991-01-16 Nucleic acid
US07/741,940 US5352775A (en) 1991-01-16 1991-08-08 APC gene and nucleic acid probes derived therefrom

Publications (1)

Publication Number Publication Date
ES2158847T3 true ES2158847T3 (es) 2001-09-16

Family

ID=26298271

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906080T Expired - Lifetime ES2158847T3 (es) 1991-01-16 1992-01-16 Mutaciones heredadas y somaticas del gen apc en el cancer colorectal del hombre.

Country Status (9)

Country Link
EP (1) EP0569527B1 (es)
AT (1) ATE199746T1 (es)
AU (1) AU1366992A (es)
CA (1) CA2100472C (es)
DE (1) DE69231734T2 (es)
DK (1) DK0569527T3 (es)
ES (1) ES2158847T3 (es)
GR (1) GR3036047T3 (es)
WO (1) WO1992013103A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689606A1 (en) * 1993-03-19 1996-01-03 The Johns Hopkins University ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
US6025127A (en) * 1994-01-14 2000-02-15 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
DE4431174A1 (de) * 1994-09-01 1996-03-07 Deutsches Krebsforsch Nachweisverfahren für tumorspezifische mRNA
WO1997018296A1 (en) * 1995-11-15 1997-05-22 University Of Utah Novel method of culturing human epithelial cells for the identification of cancer therapeutics and diagnostics
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5733732A (en) * 1996-01-03 1998-03-31 University Of Iowa Research Foundation Methods for detecting primary adhalinopathy
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5879890A (en) * 1997-01-31 1999-03-09 The Johns Hopkins University APC mutation associated with familial colorectal cancer in Ashkenazi jews
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6818404B2 (en) 1997-10-23 2004-11-16 Exact Sciences Corporation Methods for detecting hypermethylated nucleic acid in heterogeneous biological samples
DE19848665A1 (de) * 1998-10-22 2000-04-27 Bayer Ag Ein automatisierbarer Schnelltest zum direkten Nachweis der APC Resistenz Mutation mit spezifischen Primern und Probes
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
DE19933237A1 (de) * 1999-07-15 2001-01-18 Max Planck Gesellschaft Verfahren zur Bestimmung der Proliferationsaktivität von Zellen
US6271257B1 (en) * 2000-04-17 2001-08-07 Hormos Nutraceutical Oy Ltd. Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol
US20020061289A1 (en) * 2000-10-04 2002-05-23 Boman Bruce M. Stem cell-based methods for preventing and treating tumor
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
WO2007044071A2 (en) 2005-04-21 2007-04-19 Exact Sciences Corporation Analysis of heterogeneous nucleic acid samples
EP2069535B1 (en) * 2006-08-11 2013-04-10 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
DE102011008050A1 (de) * 2011-01-07 2012-07-12 Universitätsklinikum Schleswig-Holstein Verfahren zur Diagnose der familiären adenomatösen Polyposis (FAP)
CN103733355B (zh) 2011-06-30 2017-02-08 佛罗里达大学研究基金会有限公司 用于检测红外辐射的带有增益的方法和设备
US11859246B2 (en) 2013-12-11 2024-01-02 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
US11286519B2 (en) 2013-12-11 2022-03-29 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
JP6435334B2 (ja) 2013-12-11 2018-12-05 アキュラジェン ホールディングス リミテッド 稀な配列変異体を検出するための組成物および方法
AU2016334233B2 (en) 2015-10-09 2023-01-05 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
WO2017201102A1 (en) 2016-05-16 2017-11-23 Accuragen Holdings Limited Method of improved sequencing by strand identification
CA3033749A1 (en) 2016-08-15 2018-02-22 Accuragen Holdings Limited Compositions and methods for detecting rare sequence variants
US11203782B2 (en) 2018-03-29 2021-12-21 Accuragen Holdings Limited Compositions and methods comprising asymmetric barcoding
US12049665B2 (en) 2018-06-12 2024-07-30 Accuragen Holdings Limited Methods and compositions for forming ligation products
CN114539379B (zh) * 2022-03-03 2024-06-07 山东省滨州畜牧兽医研究院 Aqp1突变型基因、蛋白、细胞系及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719061D0 (en) * 1987-08-12 1987-09-16 Imp Cancer Research Fund Paten Probe
EP0440744B1 (en) * 1988-10-31 1997-12-10 The Regents Of The University Of California Products and methods for controlling the suppression of the neoplastic phenotype

Also Published As

Publication number Publication date
CA2100472A1 (en) 1992-07-17
GR3036047T3 (en) 2001-09-28
DK0569527T3 (da) 2001-07-16
AU1366992A (en) 1992-08-27
EP0569527A1 (en) 1993-11-18
DE69231734T2 (de) 2001-09-20
ATE199746T1 (de) 2001-03-15
DE69231734D1 (de) 2001-04-19
CA2100472C (en) 2009-04-07
EP0569527B1 (en) 2001-03-14
WO1992013103A1 (en) 1992-08-06

Similar Documents

Publication Publication Date Title
ES2158847T3 (es) Mutaciones heredadas y somaticas del gen apc en el cancer colorectal del hombre.
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
CY1110029T1 (el) Γονιδιο που εκφραζεται στον καρκινο του προστατη
FR2657259B1 (es)
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
TR200102577T2 (tr) Kanser Tedavisi için Casb616 Polipeptid ve Polinücleotidlerin kullanımı
MXPA03001634A (es) Polipeptido tumoral cripto.
CY1107116T1 (el) Νεες κυκλοεξυλ σουλφονες
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
WO1992002240A3 (en) Novel methods and compositions for treatment of angiogenic diseases
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
BR9609620A (pt) 2-aminocarbonil-1,2-bis(metilsulfonil)-1-(substituìda s)hidrazinas antitumorais.
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ATE367825T1 (de) Zusammensetzung und kit zur verwendung in der tumorbehandlung
MX2020013883A (es) Tratamientos oncológicos con agentes de zinc.
BR0114856A (pt) Combinação compreendendo camptotecina e um derivado de estilbeno para o tratamento de câncer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 569527

Country of ref document: ES